From tariffs to drug pricing to the FDA, biopharma CEOs find themselves pulled into policy discussions on this year’s second quarter earnings calls.

President Donald Trump threatened to levy tariffs of up to 250% on pharmaceuticals imported into the United States.

Novo Nordisk hit by slowing Ozempic sales, Tesla shareholders sue Musk over Robotaxi - Stock market news and latest business and finance updates from Wednesday ...

Novo Nordisk reported second quarter earnings a week after revising its 2025 outlook down on slower GLP-1 sales.

Trump is lying to West Virginians about lowering the price of drugs for seniors. Per the facts, drug price reductions are ...

Investing in clinical-stage biotechnology always carries significant risks, and aTyr is no exception. The company reported a $14.9 million net loss and used $15.4 million in operating cash during the ...

European shares rose Wednesday as earnings proved resilient to the tariff tumult of the second-quarter, even as another cliff-edge for U.S. levies loomed . The STOXX Europe 600 was on course for its ...

Our system provides the best of both worlds: development of new drugs and cheap options for most prescriptions. | Opinion ...

I think that's the case with Vertex. Here are seven reasons why Vertex is a no-brainer stock to buy on the dip.

Novo Nordisk cautioned on Wednesday that it expects continued competition this year from copycat versions of its Wegovy ...

Glencore Earnings Fall on Lower Coal Prices, Copper Production Challenges The commodities giant said the results reflect lower coal prices and a drop in copper production following operational ...

Getting your correct medication should be as easy as asking your doctor to prescribe it and then picking it up on the way out the door.